|
Frequently Asked Questions
Vector Core
|
Frequently Asked Questions
| Storage Conditions |
Comparison Chart
Frequently Asked Questions
Q: What is the required biosafety level for using
recombinant viruses?
Q: What are RCAs?
Q: What forms do I need to fill out for
recombinant virus production?
Q: What do I need to mark on the service request
form?
Q: How long does virus production take?
Q: Will adenovirus/lentivirus/retrovirus work well in my
cell models?
Q: How should I prepare DNA for virus production and how much does the Core
need?
Q: How much virus do I get?
Q: What's the optimal concentration
of viruses that I should use for infection?
Q: Do I need a titer?
Q: How much media should I use
during infection?
Q: Can serum be present in the media
during viral infection?
Q: For adenovirus, what are the differences between viral
particle (VP) and plaque formation unit (PFU)?
Q: What are the recommended storage conditions for
the recombinant viruses?
Q: Which viral gene delivery system
(adenovirus, retrovirus or lentivirus) is best to use for my experiments?
Q: What is the required biosafety level for using
recombinant viruses?
All viruses handled at the University of Michigan need to be registered with the UM
Institutional Biosafety Committee (IBC). The IBC determines the biosafety level
for each virus. In general, most of the recombinant viruses produced in the
Vector Core are classified as Biosafety Level II for agents considered of
ordinary potential harm. These recombinant viruses include E1, E3-deleted
adenovirus and third-generation, self-inactivating (sin) lentivirus.
Federal
regulations can be found here.
Q: Will adenovirus/lentivirus/retrovirus work well in my
cell models?
Both adenovirus and lentivirus have a wide host range in mammalian cell lines
and primary cells. Both viruses infect dividing and non-dividing cells. There
are few cell lines that cannot be infected with adenovirus or lentivirus.
Retrovirus (MMLV) host range is not as wide as lentivirus, but still works well
in many types of dividing cells. We recommend first testing your cell system
with one of our adenovirus or lentivirus reporter viruses.
Q: How should I prepare DNA for virus production and how much does the
Core need?
For adenovirus, we prefer 50 μg (minimum of 25
μg; preferably 1 μg/μl) of plasmid
linearized with either PmeI, NheI, SfiI, or SwaI (see
Protocols and Useful Links). We recommend that the DNA be heat inactivated
after digestion and a sample run on the gel to confirm proper digestion. The DNA
should then be phenol chloroform extracted, ethanol precipitated and resuspended
in water. Preparation of the plasmid is important. We do not recommend gel
extraction. For lentivirus and retrovirus, we need 100 μg and 840
μg of high
quality plasmid for the small and large scale preps, respectively.
Q: What forms do I need to fill out for
recombinant virus production?
Please see our
Instructions and Forms page.
Q: What do I need to mark on the service
request form?
The contact and billing information in the top box is required information. For
ordering product, just write in the name of the product(s) in the appropriate
box and the quantity that you request. Note: for UM customers, if you are
ordering adenovirus construction, then code AA (plaque amplification) is
required with code AT (DNA transfection for adenovirus construction). A large
scale adenovirus purification and expansion does not include a titer (code AP).
Q: How much virus do I get?
Lentivirus:
shRNA tester samples - 5, 3 ml unconcentrated supernatant.
Small scale production - 100 mls of supernatant concentrated 10X (10 mls of 10X
virus).
Large scale production - 1 liter of supernatant concentrated 10X (100 mls of 10X
virus).
Titers of unconcentrated lentivirus generally 1x106 transduced units/ml (1x107 transduced units/ml for 10X concentrated virus) with our standard rHIV vector
using GFP as the readout. Titers may vary depending on the transgene being
expressed, the system used, the quality of the proviral plasmid DNA and
titering method.
Retrovirus (MMLV):
Small scale production-VSVG env-concentrated - 100 mls of supernatant
concentrated 10X (10 mls of 10X virus).
Large scale production-VSVG env-concentrated - liter of supernatant concentrated
10X (100 mls of 10X virus).
Small scale production-ecotropic or amphotropic env-unconcentrated - 100 mls of
supernatant
Large scale production-ecotropic or amphotropic env-unconcentrated - 1 liter of
supernatant
Titers are generally 1x107 transduced units/ml for VSVG enveloped, 10X
concentrated virus and 1x106 transduced units/ml for ecotropic or amphotropic
enveloped, unconcentrated virus with our standard rMMLV vector using GFP as the
readout. Titers may vary depending on the transgene being expressed, the system
used and the quality of the proviral plasmid DNA.
Adenovirus:
The customer receives all virus that is produced. This amount varies
dramatically depending on the viral system, transgene expressed, and quality of
the starting virus. We aim for 4x1012 particles/ml. The typical yield is around
1.0-4.0x1013 total particles.
Q: How long does virus production take?
Virus production is done first come, first served. The times listed below are
estimates. The time may be longer due to large order volume or if a problem is
encountered.
Adenovirus:
Virus construction and transfection (code AT) and plaque amplification (code AA)
- 4-5 weeks. Note: this process is the most difficult and most variable. It may
take more than one attempt to make virus. This is in part because we overlay the
cells and pick viral plaques for clonal isolation to assure the highest quality
of virus.
Adenovirus purification and expansion (code AL) - 2 weeks
Titer (plaque assay) - 2-3 weeks
Lentivirus and Retrovirus:
Two weeks once we receive sufficient quantity of the proviral plasmid to perform
the transfection.
Q: What's the optimal
concentration of virus that I should use for infection?
The appropriate amount of virus used for infecting cells is very important for
the outcome of your experiments. The optimal concentration differs dramatically
between cell types. Too much virus uptake by the cells will cause cytotoxicity
(with adenovirus) and too little virus will not give you 100% infection of the
cells. The optimal concentration needs to be determined empirically. For these
pilot studies, a marker virus such as β-gal or GFP is available. For
adenovirus, optimal virus concentration for most cells is between 50 and 1000 MOI
(multiplicity of infection; MOI x # of cells = pfu required). (click
here for
protocol). For lentivirus, optimal infection may require linker molecules or
other "tricks" (click
here for protocol).
Q: Do I need a titer?
A titer is the standard for determining how much virus to add to cells or inject
into animals. Many journals will require a titer for publication. A titer (PFU/ml)
is also needed to calculate MOI. Since the percent of live viral particles (VP)
can vary drastically between any two viruses or preps, a titer is a way to
normalize between viruses. The problem with titers is that they can also be
variable depending on the type of assay used to determine the titer, the cells
used and the person performing the assay. All Vector Core viruses are prepared
the same way using standard procedures. There is very little variation in the
VP:IU (infectious unit) ratio and the titers of all the viruses that we make are
within a small range. Therefore, when using multiple viruses produced from the
Vector Core, either particles or titer is fine.
Q: How much media should I
use during infection?
We recommend the following amounts of virus-containing media for infection:
10-cm plate: 8-10 ml per plate; 6-well plate: 1 ml per well; 12-well plate: 0.5 ml
per well; 24-well plate: 0.2 ml per well. This roughly reflects the surface area
of each well or plate.
Q: Can serum be present in the
media during viral infection?
Yes, as long as it's used with caution and it comes from a fetal animal. Serum
from an animal that has been born runs a risk of having antibodies against the
virus, particularly adenovirus.
Q: For adenovirus, what are the differences
between viral particle (VP) and plaque formation unit (PFU)?
Viral particles (VPs) represent the total number of viral particles (live and
dead). The amount of viable virus varies dramatically depending on how the virus
is purified and stored. PFU (plaque formation unit) or infectious units
represents the number of infectious or live viruses. It reflects the amount of
working viruses in the preparation. VP/PFU ratio is generally 20:1 to 100:1.
Vector Core adenovirus preps are about 25:1. Multiplicity of infection (MOI) is
the number of viral copies per cell. It can also be thought of in terms of pfu
per cell. It is calculated by MOI x # of cells= pfu required.
Q: What are the recommended storage
conditions for the recombinant viruses?
We recommend that adenovirus be placed at -70°C or colder for long term storage.
NOTE: Freeze-thawing will result in loss of infectious particles. For best
results, thaw virus on ice and aliquot the amount you typically use per
experiment into separate microfuge tubes. DO NOT freeze-thaw more than two
times.
Adenovirus Storage Buffer: The adenovirus is suspended in 10 mM Tris-HCl pH 7.4,
137 mM NaCl, 5 mM KCl, 1 mM MgCl2 to which glycerol has been added to 10% by
volume. Lentivirus and MMLV storage buffer: DMEM or as requested.
Q: What are RCAs?
Replication competent adenoviruses (RCAs) are wild-type like viruses in a
population of replication-deficient viruses. RCAs result from a crossover event
where the deleted E1 region of the virus re-inserts itself into the virus while
being grown in packaging cells. Once this happens, the RCA adenovirus will
replicate without the need of a packaging cell line and outgrow recombinant
adenovirus in packaging cells. To avoid the occurrence of RCA, viruses should
not be serially propagated. Recombinant adenovirus with high RCA can be rescued
by clonal isolation after plaque assay.
Q: Which viral gene delivery system
(adenovirus, retrovirus or lentivirus) is best to use for my experiments?
Adenovirus: 100% gene delivery efficiency in most cell types including dividing
and non-dividing or primary cells. It's a high expression, transient vector
system. There is no integration with the host system. Protocols involved in
developing recombinant adenovirus are complicated. Lentivirus: Greater than 80%
efficiency in most dividing cell types. Efficiency is lower in most non-dividing
cell types and in most suspension cells. Lentivirus is a stable, low expression
vector system due to integration into the host genome. Lentivirus may lead to
mutation of genes in the host system. Retrovirus (MMLV): gives <40% efficiency
in most cell types, and requires active cell division. MMLV, like lentivirus, is
a stable, low expression vector system due to integration into the host genome.
MMLV may lead to mutation of genes in the host system.
| Vector Core Storage Buffer | Temperature | Other | |
| Adenovirus | The adenovirus is suspended in 10 mM Tris-HCl pH 7.4, 137 mM NaCl, 5 mM KCl, 1 mM MgCl2 to which glycerol has been added to 10% by volume | -80° C | Avoid freeze/thaw |
| Lentivirus | Any | -80° C | Freeze-thaw a maximum of three times |
| MoMLV | Any | -80° C | Avoid freeze/thaw |
| Plasmid | Any | -80° C |
| Viral Vector | Maximum Insert Size | Preferential Target Cells | Common Research Applications | General Advantages |
| Adenovirus | 7.5 kb | Transduces cells with CAR & avB integrins receptors very well
Will transiently transduce many primary cells at high efficiency |
In vitro and in vivo transient transgene expression | Ease of use in vitro and in vivo
High titers |
| Lentivirus | > 6.5 kb | Will transduce (via integration) differentiated non-dividing cells including most hematopoietic-derived cells and neurons, as well as dividing cells. | Stable integration allows for both production of permanent cell lines for in vitro applications and long-term modifications for in vivo and ex vivo applications | Transfects dividing and non-dividing cells Integration into genome Wide spectrum of target cells |
| Retrovirus (MoMLV) | > 6.5 kb | Transfects and integrates into wide variety of dividing cells | Stable integration allows for both production of permanent cell lines for in vitro applications and long-term modifications for in vivo and ex vivo applications | Integration into genome Wide spectrum of target cells |


